Global Tendinitis Treatment Market Projected To Grow Radiantly By 2030; Asserts MRFR Unleashing Industry Forecast

Pune, India, January, 2022/MRFR Press Release/- Market Research Future published a Half-Cooked research report on “Global Tendinitis Treatment Market Research Report - Forecast to 2030”– Market Analysis, Scope, Progress, Trends and Forecast to 2030.

Global Tendinitis Treatment Market - Overview

Tendinitis is the inflammation of the tendon, thick cords that attach the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter's syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-steroidal anti-inflammatory drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.

Global tendinitis treatment market is expected to grow at the CAGR of ~3.7% during the forecast period and is estimated to reach USD 24,5452 Million by 2030. According to a recent study report published by the Market Research Future, the global tendinitis treatment market is expected to gain eminence over the forecast period. The market is forecasted to demonstrate a steady growth by 2030, surpassing its previous growth records in terms of value with a constant CAGR during the anticipated period (2022 – 2030).

Rising prevalence of sport injuries has spurred the growth of this market. According to the U.S. centers for diseases control, around 10% of kids and teen participating in the sports suffer from minor or major type of injury. Moreover, increasing geriatric population, and growing prevalence diabetes and rheumatoid arthritis are import factors accelerating the growth of the market. Rising awareness about sport injuries, and growing emphasis on early diagnosis and treatment of sport injuries also influence the market growth. Additionally, availability of skilled healthcare professionals in the field of sports medicine is another important factor driving the market. However, use of pain reliever or OTC drugs may result in side effects, restraining the growth of the market.

Global Tendinitis Treatment Market - Competitive Analysis

Almatica Pharma, Inc. (US), AstraZeneca (US), Bayer (Germany), Boehringer Ingelheim Pharmaceuticals, Inc. (US), Merck & Co., Inc (US), Pfizer (US), and others are some of the prominent players at the forefront of competition in the Global Tendinitis Treatment Market and are profiled in MRFR Analysis. 

The market for tendinitis treatment is characterised by the presence of several well-established and small players, the global market of tendinitis treatment appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The tendinitis treatment market appears to be highly competitive owing to the presence of several large and small key players accounting for a substantial market share. Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well. Furthermore, the companies such as Abbott, AstraZeneca, Teva, and Pfizer are well-established in European market. The major four players namely Abbott, AstraZeneca, Teva, and Pfizer accounted for more than 17% share of the Americas and Europe tendinitis market.

In April 2017, Pfizer entered into a merger with Allergan to gain access for Allergan's portfolio including Botox, Viagra, the Prevnar pneumonia vaccine, and treatments for ailments including Alzheimer’s and rheumatoid arthritis.

Furthermore, in July 2017, Merck & Co.Inc & AstraZeneca entered into strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types.   

Furthermore, in November 2016, AstraZeneca announced a licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc., for the global rights to MEDI2070.

Moreover, May 2014, the company acquired Merck & Co., Inc.’s non-prescription business to become the OTC leader in North America and Latin America & achieve top global positions in key OTC product categories.

Therefore, the growing key business strategies will help the key competitors to expand their presence in various parts of the globe for their competitive products and will has spurred the growth of the market.  

Browse Full Report @ https://www.marketresearchfuture.com/reports/tendinitis-treatment-market-3876